Cytoprotection with amifostine in radiotherapy or combined radio- chemotherapy of head and neck cancer;Zytoprotektion mit amifostin in der strahlentherapie bzw. Strahlen- /chemotherapie von kopf-hals-tumoren

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL.4, 1999, Pages 30-33

  Altmann, Stefan ^b   Hoffmanns, Hans ^a  

^a Krankenhaus Maria Hilf Monchengladbach   (Germany)

^b Krankenhaus Maria Hilf   (Germany)

Author keywords

Amifostine; Head an neck cancer; Radioprotection

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DRUG INDUCED DISEASE; HEAD CANCER; HUMAN; MUCOSA INFLAMMATION; NECK CANCER; RADIATION PROTECTION; SKIN TOXICITY; STOMATITIS;

ADULT; AGED; AMIFOSTINE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYTOPROTECTION; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; MOUTH MUCOSA; POSTOPERATIVE CARE; PREOPERATIVE CARE; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; STOMATITIS; TIME FACTORS;

EID: 0032726143     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Brizel D, Sauer R, Wannenmacher M. et al. Randomized phase III trial of radiation + amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 1998;17:1487.
2. Büntzel J, Schuth J. Küttner K, et al. Radiochcmotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 1998;6: 155-60.
3. Büntzel J, Glatzel M, Fröhlich D, et al. Intensification of radiochemotherapy with amifostine in head and neck cancer. Proc Am Soc Clin Oncol 1998;17:1555.
4. DeVita VT Jr, Hellman S, Jaffe ES. Hodgkin's diaease. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer, 4th edn. Philadelphia: Lippincott, 1993:1819-58.
5. Kath R, Peters HD. Höffken K. Amifostin. Onkologe 1997;3:191-8.
6. Kemp G, Rose P, Lurain J, et al. Amifostine pretteatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-12.
7. Kligerman MM, Liu T, Liu Y, et al. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. Int J Radiat Oncol Biol Phys 1992;22:799-802.
8. Lane DR, Pajesu TS, Büntzel J, et al. Analyzing clinical and economic benefits of novel therapeutic agents in phase II clinical trials. Proc Am Soc Clin Oncol 1998;17:1607.
9. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Statist Assoc 1963;58:690-700.
10. McDonald S. Meyerowitz C, Smudzin T. Preliminary results of apilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1904; 29:747-54.
11. Rieth A, Schuth J, Kudielka RA. Cyctoprotection in chemo- and radiotherapy with amifostine (Ethyol): A new strategy in oncology. Onkologie 1996;19:315-20.
12. Seegenschmiedt MH, Sauer H, Müller RP. Interdisziplinäre Dokumentation von akuten Nebenwirkungen in der Onkologie: Common Toxicity Criteria (CTC). Forum DKG 1998;13:178-88.
13. Spencer CM, Goa KL. Amifostine - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995;50:1001-31.
14. Wassermann TH, Phillips TL, Ross G, et al. Differential protection against cytotoxic chemotherapeutic effects on hone marrow CFUs by WR-2721. Cancer Clin Trials 1981;4:3-6.